期刊文献+
共找到190篇文章
< 1 2 10 >
每页显示 20 50 100
Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation 被引量:10
1
作者 Abdulmuttalip Simsek Sinan Levent Kirecci +5 位作者 Onur Kucuktopcu Faruk Ozgor Mehmet Fatih Akbulut Omer Sarilar Unsal Ozkuvanci Zafer Gokhan Gurbuz 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第5期725-727,I0008,I0009,共5页
Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE), Our objective in this study was to characterize the efficac... Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE), Our objective in this study was to characterize the efficacy of on-demand dapoxetine (30 and 60 mg) and daily paroxetine (20 mg) usage in treating PE, We conducted a 1 month study involving a total of 150 patients. Patients were divided into three groups of 50, Group 1 were treated with on-demand dapoxetine (30 mg), Group 2 with on-demand dapoxetine (60 mg) and Group 3 with daily paroxetine (20 rag), Our outcome measurement was increased from baseline intravaginal ejaculatory latency time (IELT) after treatment, The IELT increased from baseline to posttreatment by 117%, 117% and 170% in the paroxetine group (P 〈 0,01), 30 mg dapoxetine group (P 〈 0,01) and 60 mg dapoxetine group (P 〈 0.01), respectively, The increase from baseline IELT were similar for the 30 mg dapoxetine and paroxetine groups (P 〉 0,05), while the 60 mg dapoxetine group had a larger posttreatment IELT increase compared with the 30 mg dapoxetine (P〈 0.05) and paroxetine (P〈 0.01) groups, Dapoxetine (60 mg) 1-3 h before planned intercourse is a very effective treatment modality for PE. However, an on-demand dose of 30 mg dapoxetine is no more effective than the currently prescribed paroxetine treatment. 展开更多
关键词 DAPOXETINE PAROXETINE premature ejaculation selective serotonin reuptake inhibitor
下载PDF
Selective serotonin reuptake inhibitors and Alzheimer’s disease 被引量:5
2
作者 Bernadette Mdawar Elias Ghossoub Rita Khoury 《Neural Regeneration Research》 SCIE CAS CSCD 2020年第1期41-46,共6页
Given the failure to develop disease-modifying therapies for Alzheimer’s disease(AD),strategies aiming at preventing or delaying the onset of the disease are being prioritized.While the debate regarding whether depre... Given the failure to develop disease-modifying therapies for Alzheimer’s disease(AD),strategies aiming at preventing or delaying the onset of the disease are being prioritized.While the debate regarding whether depression is an etiological risk factor or a prodrome of AD rages on,a key determining factor may be the timing of depression onset in older adults.There is increasing evidence that untreated early-onset depression is a risk factor and that late-onset depression may be a catalyst of cognitive decline.Data from animal studies have shown a beneficial impact of selective serotonin reuptake inhibitors on pathophysiological biomarkers of AD including amyloid burden,tau deposits and neurogenesis.In humans,studies focusing on subjects with a prior history of depression also showed a delay in the onset of AD in those treated with most selective serotonin reuptake inhibitors.Paroxetine,which has strong anticholinergic properties,was associated with increased mortality and mixed effects on amyloid and tau deposits in mice,as well as increased odds of developing AD in humans.Although most of the data regarding selective serotonin reuptake inhibitors is promising,findings should be interpreted cautiously because of notable methodological heterogeneity between studies.There is thus a need to conduct large scale randomized controlled trials with long follow up periods to clarify the dose-effect relationship of specific serotonergic antidepressants on AD prevention. 展开更多
关键词 Alzheimer’s disease AMYLOIDOGENESIS animal models ANTIDEPRESSANT depression onset delay prevention selective serotonin reuptake inhibitor ssri
下载PDF
Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A populationbased cohort study 被引量:2
3
作者 Wan-Tzu Lin Yi-Jun Liao +4 位作者 Yen-Chun Peng Chung-Hsin Chang Ching-Heng Lin Hong-Zen Yeh Chi-Sen Chang 《World Journal of Gastroenterology》 SCIE CAS 2017年第19期3513-3521,共9页
AIM To investigate the relationship between selective serotonin reuptake inhibitor(SSRI)use and the subsequent development of irritable bowel syndrome(IBS).METHODS This retrospective,observational,population-based coh... AIM To investigate the relationship between selective serotonin reuptake inhibitor(SSRI)use and the subsequent development of irritable bowel syndrome(IBS).METHODS This retrospective,observational,population-based cohort study collected data from Taiwan’s National Health Insurance Research Database.A total of 19653patients newly using SSRIs and 78612 patients not using SSRIs,matched by age and sex at a ratio of 1:4, were enrolled in the study from January 1,2000 to December 31,2010.The patients were followed until IBS diagnosis,withdrawal from the National Health Insurance system,or the end of 2011.We analyzed the effects of SSRIs on the risk of subsequent IBS using Cox proportional hazards regression models.RESULTS A total of 236 patients in the SSRI cohort(incidence,2.17/1000 person-years)and 478 patients in the comparison cohort(incidence,1.04/1000 person-years)received a new diagnosis of IBS.The mean follow-up period from SSRI exposure to IBS diagnosis was 2.05years.The incidence of IBS increased with advancing age.Patients with anxiety disorders had a significantly increased adjusted hazard ratio(a HR)of IBS(a HR=1.33,95%CI:1.11-1.59,P=0.002).After adjusting for sex,age,urbanization,family income,area of residence,occupation,the use of anti-psychotics and other comorbidities,the overall a HR in the SSRI cohort compared with that in the comparison cohort was1.74(95%CI:1.44-2.10;P<0.001).The cumulative incidence of IBS was higher in the SSRI cohort than in the non-SSRI cohort(log-rank test,P<0.001).CONCLUSION SSRI users show an increased risk of subsequent diagnosis of IBS in Taiwan. 展开更多
关键词 Brain-gut axis Irritable bowel syndrome selective serotonin reuptake inhibitor
下载PDF
Mouse strain differences in selective serotonin reuptake inhibitors sensitivity correlates with serotonin transporter binding and function
4
作者 JIN Zeng-liang CHEN Xiao-fei +4 位作者 LI Xiao-rong XIONG Jie ZHENG Yuan-yuan GAO Na-na LI Yun-feng 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2018年第9期710-711,共2页
OBJECTIVE Selective serotonin reuptake inhibitors(SSRIs) bind 5-HT transporters,leading to the accumulation of 5-HT and amelioration of depression.Although different mouse strain showed different sensitivity to SSRIs ... OBJECTIVE Selective serotonin reuptake inhibitors(SSRIs) bind 5-HT transporters,leading to the accumulation of 5-HT and amelioration of depression.Although different mouse strain showed different sensitivity to SSRIs in mouse models of depression,the reason for these strain differences remains unclear.Here,therefore,in the present study,we examined immobility time and locomotor activity in two mouse strains,namely,C57BL/6 J and DBA/2 J mice,and the effects of the SSRIs fluoxetine.Furthermore,we analyzed 5-HT transporter binding and reuptake inhibition in both strains to explore their relationship with the immobility and locomotor activity effects of the three SSRIs in these two mouse strains.METHODS Strain differences in SSRI effects in the tail suspension test(TST) and forced swimming test(FST).To initiate our studies,we sought to confirm that SERT strain variation did not alter SERT protein expression,5-HT recognition,or uptake activity when expressed in C57BL/6 J and DBA/2 J mice.Radioligand binding assays were conducted to determine the affinity of the SSRIs for the 5-HT transporters in the two mouse strains.RESULTS SSRI citalopram dose-dependently reduced immobility time in both the FST and TST in DBA/2 J but not C57BL/6 J mouse strains,whereas fluoxetine showed opposite results.Paroxetine reduced immobility time similarly in both strains.The affinity of citalopram for the 5-HT transporter in DBA/2 J mice was 700-fold higher than that for in C57BL/6 J mice,whereas the affinity of fluoxetine in C57BL/6 J mice was 100-fold higher than that in the DBA/2 J mouse.Furthermore,High citalopram concentrations were required to [3 H]5-HT uptake in C57BL/6 J but not DBA/2 J mouse cortical synaptosomes,whereas fluoxetine also showed opposite results.CONCLUSION Immobility duration depends on 5-HT transporter binding levels,leading to apparent strain differences in immobility time in FST and TST.Furthermore,differences in 5-HT transporter binding may cause variations in SSRI responses on behaviors.SERT mutation mice maintained sensitivity to paroxetine,an antidepressant that is unaffected by the mouse mutation.Therefore,the background strain of these mice likely contributes to the acute behavioral actions of SSRIs in immobility time.These differences may help to explain some of the discrepancies in studies that used these strains of mice to examine the role of 5-HT in mouse models of depression.Future studies should investigate additional neural substrates and molecular mechanisms underlying strain variations in mouse models of depression to help identify genetic predispositions to this disorder in humans. 展开更多
关键词 antidepressants mouse STRAINS selective serotonin reuptake inhibitorS
下载PDF
Fluoxetine,a selective serotonin reuptake inhibitor used clinically,improves bladder function in a mouse model of moderate spinal cord injury
5
作者 Long Ma Jing-Yuan Tang +6 位作者 Jin-Yong Zhou Chen Zhu Xin Zhang Ping Zhou Qiu Yu Yan Wang Xiao-Jian Gu 《Neural Regeneration Research》 SCIE CAS CSCD 2021年第10期2093-2098,共6页
After spinal cord injury,the upward conduction of the spinal cord is lost,resulting in the loss of micturition control,which manifests as detrusor sphincter dyssynergia and insufficient micturition.Studies have shown ... After spinal cord injury,the upward conduction of the spinal cord is lost,resulting in the loss of micturition control,which manifests as detrusor sphincter dyssynergia and insufficient micturition.Studies have shown that serotonergic axons play important roles in the control of the descending urination tract.In this study,mouse models of moderate spinal cord contusions were established.The serotonin agonists quipazine(0.2 mg/kg),8-hydroxy-2-(di-n-propylamino)tetralin(8-OH-DAPT,0.1 mg/kg),buspirone(1 mg/kg),sumatriptan(1 mg/kg),and rizatriptan(50 mg/kg),the serotonin reuptake inhibitors fluoxetine(20 mg/kg)and duloxetine(1 mg/kg),and the dopamine receptor agonist SKF-82197(0.1 mg/kg)were intraperitoneally administered to the model mice 35 days post-injury in an acute manner.The voided stain on paper method and urodynamics revealed that fluoxetine reduced the amount of residual urine in the bladder and decreased bladder and external urethral sphincter pressure in a mouse model of moderate spinal cord injury.However,fluoxetine did not improve the micturition function in a mouse model of severe spinal cord injury.In contrast,the other serotonergic drugs had no effects on the micturition functions of spinal cord injury model mice.This study was ethically approved by the Institutional Animal Care and Use Committee of Jiangsu Province Hospital of Chinese Medicine(approval No.2020DW-20-02)on September 11,2020. 展开更多
关键词 BLADDER external urethral sphincter FLUOXETINE MICTURITION selective serotonin reuptake inhibitor spinal cord injury URODYNAMICS voided stain on paper measurement
下载PDF
Serotonin syndrome controversies:A need for consensus
6
作者 Sanjay Prakash Chetsi S Shah Anurag Prakash 《World Journal of Critical Care Medicine》 2024年第2期150-158,共9页
Serotonin syndrome(SS)is a drug-induced clinical syndrome resulting from increased serotonergic activity in the central nervous system.Although more than seven decades have passed since the first description of SS,it ... Serotonin syndrome(SS)is a drug-induced clinical syndrome resulting from increased serotonergic activity in the central nervous system.Although more than seven decades have passed since the first description of SS,it is still an enigma in terms of terminology,clinical features,etiology,pathophysiology,diagnostic criteria,and therapeutic measures.The majority of SS cases have previously been reported by toxicology or psychiatry centers,particularly in people with mental illness.However,serotonergic medications are used for a variety of conditions other than mental illness.Serotonergic properties have been discovered in several new drugs,including over-the-counter medications.These days,cases are reported in non-toxicology centers,such as perioperative settings,neurology clinics,cardiology settings,gynecology settings,and pediatric clinics.Overdoses or poisonings of serotonergic agents constituted the majority of the cases observed in toxicology or psychiatry centers.Overdose or poisoning of serotonergic drugs is uncommon in other clinical settings.Patients may develop SS at therapeutic dosages.Moreover,these patients may continue to use serotonergic medications even if they develop mild to moderate SS due to several reasons.Thus,the clinical presentation(onset,severity,and clinical features)in such instances may not exactly match what toxicologists or psychiatrists observe in their respective settings.They produce considerable diversity in many aspects of SS.However,other experts discount these new developments in SS.Since SS is a potentially lethal illness,consensus is required on several concerns related to SS. 展开更多
关键词 serotonin serotonin syndrome serotonin toxicity selective serotonin reuptake inhibitors Antidepressants CYPROHEPTADINE
下载PDF
SSRI治疗首发为抑郁发作的双相障碍患者对自杀风险的相关因素分析 被引量:8
7
作者 李则挚 苑成梅 +8 位作者 黄佳 洪武 胡莺燕 曹岚 卢卫红 王勇 吴志国 陈俊 方贻儒 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2011年第12期715-718,共4页
目的探讨双相障碍首次抑郁发作使用SSRI类抗抑郁剂治疗后,出现自杀风险的相关因素。方法回顾性记录177例以抑郁发作为首次发作形式的双相抑郁障碍患者人口学资料和临床特征,并比较它们在没有出现自杀组和出现自杀组之间的差异,采用逐步L... 目的探讨双相障碍首次抑郁发作使用SSRI类抗抑郁剂治疗后,出现自杀风险的相关因素。方法回顾性记录177例以抑郁发作为首次发作形式的双相抑郁障碍患者人口学资料和临床特征,并比较它们在没有出现自杀组和出现自杀组之间的差异,采用逐步Logistic回归方法进行分析,受试者工作特征曲线(ROC)与Hosmer-Lemeshow分别评估危险因素模型的准确度和拟合优度。结果没有出现自杀风险患者154例,出现自杀风险患者23例。出现自杀风险的患者组中饮酒史、心境障碍家族史、有易激惹症状、绝望感和伴随精神病性症状的比例高于未出现自杀风险的患者组(均P<0.05)。进一步回归分析显示,使用SSRI类抗抑郁剂治疗而导致自杀风险的相关因素为:易激惹(OR=4.04,95%CI:1.40~11.67,P<0.05),有精神病性症状(OR=6.23,95%CI:1.41~27.56,P<0.05)。ROC为0.71。Hosmer-Lemeshow为0.58。结论易激惹症状、精神病性症状是双相障碍首次抑郁发作予SSRI治疗出现自杀风险的潜在预测因素。 展开更多
关键词 双相障碍 首发抑郁发作 自杀风险 五羟色胺再摄取抑制剂
下载PDF
SSRI和SNRI类抗抑郁药的不良反应 被引量:15
8
作者 张英 崔向丽 +4 位作者 杨萍 贾颖 刘静 潘华 赵志刚 《中国药物警戒》 2010年第9期554-556,共3页
目的研究SSRI和SNRI类抗抑郁药不良反应的临床表现和处理措施,为临床医师合理用药提供参考。方法收集我院2010年上半年神经内科门诊使用SSRI或SNRI类抗抑郁药出现不良反应的24例抑郁或焦虑病例,分析其具体不良反应临床表现和相应的处理... 目的研究SSRI和SNRI类抗抑郁药不良反应的临床表现和处理措施,为临床医师合理用药提供参考。方法收集我院2010年上半年神经内科门诊使用SSRI或SNRI类抗抑郁药出现不良反应的24例抑郁或焦虑病例,分析其具体不良反应临床表现和相应的处理措施。结果 SSRI/SNRI最常见的不良反应是胃肠道反应,其他少见的有精神症状、自主神经功能障碍和椎体外系反应等。结论尽管SSRI和SNRI都是比较安全的抗抑郁药物,临床医师应该注意监测其不良反应,并掌握处理措施。 展开更多
关键词 5-羟色胺再摄取抑制剂 5-羟色胺/去甲肾上腺素再摄取抑制剂 不良反应 处理措施
下载PDF
MECT联合SSRI类药物治疗难治性抑郁症有效性和安全性Meta分析 被引量:8
9
作者 周林科 郭菁 +2 位作者 徐忆 王啸 谢鹏 《重庆医科大学学报》 CAS CSCD 北大核心 2014年第6期853-857,共5页
目的:评价改良电休克(modified electroconvulsive therapy,MECT)联合选择性5-羟色胺再摄取抑制剂(selective serotonin reuptake inhibitor,SSRI)治疗难治性抑郁症的有效性和安全性。方法:通过检索Cochrane Library、PubMed、Web of Kn... 目的:评价改良电休克(modified electroconvulsive therapy,MECT)联合选择性5-羟色胺再摄取抑制剂(selective serotonin reuptake inhibitor,SSRI)治疗难治性抑郁症的有效性和安全性。方法:通过检索Cochrane Library、PubMed、Web of Knowledge、EBSCO、中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)、万方数据库(CECDB)、维普中文科技期刊全文数据库(CQVIP),检索年限不限,筛选随机对照试验(randomized controlled trials,RCTs),并对纳入文献进行质量评价和数据提取,用Review manager 5.0软件对纳入的RCTs进行Meta分析。结果:纳入7个RCTs共461名患者,其中MECT联合治疗组230例,SSRI药物治疗组231例。Meta分析结果指出MECT联合治疗组患者治愈率和有效率均高于SSRI药物治疗组,差异具有统计学意义(分别为治愈率Z=4.52,P=0.000;有效率Z=7.71,P=0.000),且副反应中MECT联合治疗组中近事记忆障碍的发生率要高于SSRI药物治疗组(P=0.013),其余的副反应发生率比较均无统计学意义(P>0.05)。结论:与单独SSRI药物治疗相比,MECT联合SSRI治疗可明显提高难治性抑郁症患者的有效率和治愈率,具有临床指导意义。 展开更多
关键词 改良电休克 电休克 选择性5-羟色胺再摄取抑制剂 难治性抑郁症 META分析
下载PDF
基于美国FAERS数据库抗抑郁药物与胎儿及新生儿的不良事件信号分析
10
作者 时贯宏 王淇 +5 位作者 孙昊 陈雁杰 储紫雁 蒋傲 汤在祥 刘静芳 《中国药物警戒》 2024年第6期687-692,共6页
目的基于美国食品药品监督管理局不良事件报告系统(FAERS)挖掘抗抑郁药物的使用与胎儿及新生儿不良事件的风险信号,为临床安全合理用药提供参考。方法筛选FAERS数据库2004年1月1日至2022年12月31日中怀疑抗抑郁药的不良事件报告,并通过... 目的基于美国食品药品监督管理局不良事件报告系统(FAERS)挖掘抗抑郁药物的使用与胎儿及新生儿不良事件的风险信号,为临床安全合理用药提供参考。方法筛选FAERS数据库2004年1月1日至2022年12月31日中怀疑抗抑郁药的不良事件报告,并通过报告比值比(ROR)法和比例报告比值比(PRR)法挖掘抗抑郁药与胎儿及新生儿之间的不良事件信号。结果共有14492例儿胎儿及新生儿异常的病例纳入研究,其中胎儿组5546例,新生儿组病例8946例。药物方面,分别有68.97%、56.35%的胎儿不良事件信号和新生儿不良事件信号为选择性5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药产生。不良事件方面,51.72%胎儿不良事件信号与羊水相关,20.99%的新生儿不良事件信号与呼吸系统异常相关。对产生的不良事件信号进行二次筛选后,西酞普兰和文拉法辛信号突出,且存在说明书未载明信号。结论抗抑郁药物的整体信号特征与现有的安全性资料基本一致,但通过分组分析仍然发现了如胎儿羊水异常、新生儿心脏方面等说明书未载明不良事件,临床使用时应重点关注。 展开更多
关键词 抗抑郁药物 选择性5-羟色胺再摄取抑制剂 胎儿及新生儿 美国食品药品监督管理局不良事件报告系统 报告比值比法 比例报告比值比法 药物安全 不良事件 信号
下载PDF
快速色氨酸耗竭试验对SSRIs药物治疗后抑郁症患者的心境和睡眠脑电图影响的系统评价和Meta分析 被引量:1
11
作者 王嘉佳 陈奕晨 +1 位作者 马艳红 谢鹏 《重庆医学》 CAS CSCD 北大核心 2011年第21期2089-2093,共5页
目的通过系统评价和Meta分析方法对比不同研究中快速色氨酸耗竭(TD)试验对经选择性5-羟色胺(5-HT)再摄取抑制剂(SSRIs)药物治疗后抑郁症患者的心境和睡眠脑电图的影响,以研究TD试验在该类抑郁症患者中作用的有效性。方法计算机检索PubMe... 目的通过系统评价和Meta分析方法对比不同研究中快速色氨酸耗竭(TD)试验对经选择性5-羟色胺(5-HT)再摄取抑制剂(SSRIs)药物治疗后抑郁症患者的心境和睡眠脑电图的影响,以研究TD试验在该类抑郁症患者中作用的有效性。方法计算机检索PubMed、Cochrane图书馆、Web of Science、Embase、CBM、CNKI等相关国内外数据库,全面搜集将TD试验用于经SSRIs药物治疗后抑郁症患者研究的所有临床随机对照研究(RCT),按照Jadad标准对纳入文献进行质量分析,并使用RevMan4.2软件进行Meta分析,对不能合并的数据结果进行系统评价。结果最终纳入2篇高质量RCT研究,Jadad评分均在3分以上。系统评价结果显示,TD组研究对象体内色氨酸浓度明显降低,达到了色氨酸耗竭的标准。Meta分析结果显示,TD组患者在汉密尔顿焦虑量表-19(HRSA-19)评分[WMD 1.37、95%CI(0.76,1.99)、P<0.001]、心境量表(POMS)中的迷惑评分[WMD1.179、5%CI(0.44,1.91)、P=0.002]、睡眠相关分析中的TST值[WMD 127、95%CI(1.5,23.9)、P=0.03]、SL值[WMD-8.11、95%CI(-12.24,-3.98)、P=0.01]、RD值[WMD 0.17、95%CI(0.04,0.31)、P=0.01]以及S1值[WMD 2.52、95%CI(-0.02,5.07)、P=0.05]与对照组比较差异有统计学意义(P<0.05)。结论本研究结果证明TD试验能够诱导经SSRIs药物治疗后的抑郁症患者出现抑郁情绪及迷惑情绪,同时能影响该类患者的睡眠周期相关参数,包括缩短快动眼潜时、增加快动眼期比例、增加快动眼期内动眼频率等。而对于其他检测指标,目前尚没有足够的证据能够证明其组间差异性。受纳入研究质量限制,上述结果还有待开展更多高质量的临床RCT试验来进一步证实。 展开更多
关键词 快速色氨酸耗竭 抑郁症 选择性5-羟色胺(5-HT)再摄取抑制剂 系统评价 META分析
下载PDF
调神疏肝法针刺结合SSRI类药物治疗抑郁症临床研究 被引量:4
12
作者 蔡骏逸 丁国安 +2 位作者 侯乐 童梓顺 徐琰 《新中医》 CAS 2018年第12期191-193,共3页
目的:观察调神疏肝法针刺结合选择性5-羟色胺再摄取抑制剂(SSRI)类药物治疗抑郁症的临床疗效和安全性。方法:纳入82例抑郁症肝气郁结证或忧郁伤神证患者,随机分为治疗组和对照组各41例。2组均使用SSRI类抗抑郁药治疗,治疗组加用调神疏... 目的:观察调神疏肝法针刺结合选择性5-羟色胺再摄取抑制剂(SSRI)类药物治疗抑郁症的临床疗效和安全性。方法:纳入82例抑郁症肝气郁结证或忧郁伤神证患者,随机分为治疗组和对照组各41例。2组均使用SSRI类抗抑郁药治疗,治疗组加用调神疏肝法针刺,2组均治疗6周。分别于治疗前及治疗后1、2、4、6周采用24项汉密尔顿抑郁量表(HAMD)和Asberg氏抗抑郁剂副反应量表(SERS)评定患者的抑郁症状和用药安全性。结果:治疗6周后,治疗组疗效优于对照组,差异有统计学意义(P <0.05)。治疗1周,治疗组HAMD评分较治疗前降低,差异有统计学意义(P <0.01),对照组治疗前后评分无统计学差异(P>0.05);治疗2、4、6周,2组HAMD评分均低于治疗前,差异均有统计学意义(P <0.05);治疗1周、6周,治疗组HAMD评分均低于对照组,差异均有统计学意义(P <0.05)。治疗1周后,治疗组的SERS评分均低于对照组,差异均有统计学意义(P <0.01)。结论:应用调神疏肝法针刺结合SSRI类药物治疗抑郁症肝气郁结证或忧郁伤神证能够提高临床治愈率,改善抑郁症状,并且减少了药物的副反应,是一种安全有效的治疗手段。 展开更多
关键词 抑郁症 肝气郁结证 忧郁伤神证 针刺 调神疏肝法 选择性5-羟色胺再摄取抑制剂(ssri) 汉密尔顿抑郁量表(HAMD) 抗抑郁剂副反应量表(SERS)
下载PDF
SSRI类药物对抑郁症患者esRAGE水平及血糖的影响 被引量:1
13
作者 杨孔军 刘铁榜 +6 位作者 荣晗 冯飞 杨海晨 彭江发 位照国 齐立国 邓小敏 《精神医学杂志》 2011年第3期183-185,共3页
目的探讨SSRI类药物对抑郁症患者血清内源性分泌型糖基化终产物受体(esRAGE)水平及血糖的影响。方法采用SSRI类药物对28例抑郁症患者进行为期6周的治疗,分别在治疗前和治疗6周后,用酶联免疫法测定抑郁症患者血清中esRAGE浓度和血糖水平... 目的探讨SSRI类药物对抑郁症患者血清内源性分泌型糖基化终产物受体(esRAGE)水平及血糖的影响。方法采用SSRI类药物对28例抑郁症患者进行为期6周的治疗,分别在治疗前和治疗6周后,用酶联免疫法测定抑郁症患者血清中esRAGE浓度和血糖水平,并与34例正常对照者比较。结果 (1)抑郁症组治疗后esRAGE浓度[(0.56±0.17)ng/ml]高于治疗前[(0.49±0.21)ng/ml],但均低于正常对照组[(0.66±0.10)ng/ml],组间比较差异有显著统计学意义(P<0.001)。(2)抑郁症组治疗后空腹血糖[(4.91±0.50)mmol/L]低于治疗前[(5.38±0.39)mmol/L],差异有显著统计学意义(P=0.000),但与正常对照组空腹血糖[(5.08±0.41)mmol/L]比较差异无统计学意义(P=0.172)。(3)Pearson相关分析显示,esRAGE与空腹血糖成中等程度负相关(P<0.05)。结论 SSRI类药物能升高抑郁症患者的esRAGE水平,同时降低血糖水平。 展开更多
关键词 选择性5-HT再摄取抑制剂 抑郁症 内源性分泌型糖基化终产物受体 空腹血糖
下载PDF
阿戈美拉汀与SSRIs治疗抑郁障碍疗效的Meta分析 被引量:1
14
作者 翁赛峥 林晖 +4 位作者 连宁 邹锦山 彭玲武 丛伟东 陈华云 《临床合理用药杂志》 2022年第16期23-26,共4页
目的比较阿戈美拉汀与选择性五羟色胺(5-HT)再摄取抑制剂(SSRIs)治疗抑郁障碍的疗效,为临床治疗提供循证医学参考。方法通过Medline、Pub Med、Wiley online library数据库检索英文文献,采用汉密尔顿抑郁量表(HAMD)及汉密尔顿焦虑量表(H... 目的比较阿戈美拉汀与选择性五羟色胺(5-HT)再摄取抑制剂(SSRIs)治疗抑郁障碍的疗效,为临床治疗提供循证医学参考。方法通过Medline、Pub Med、Wiley online library数据库检索英文文献,采用汉密尔顿抑郁量表(HAMD)及汉密尔顿焦虑量表(HAMA)评分减分作为抑郁症状及焦虑症状的改善指标,采用Rev Man 5.2统计软件进行Meta分析,比较阿戈美拉汀与SSRIs的疗效。结果最终纳入符合标准的文献6篇。阿戈美拉汀与SSRIs治疗抑郁症状[SMD=0.06(95%CI:-0.03,0.14)]与焦虑症状的改善效果[MD=0.12(95%CI:-0.82,1.06)]均无显著差异(P>0.05)。结论阿戈美拉汀与SSRIs治疗抑郁障碍的疗效相当。 展开更多
关键词 阿戈美拉汀 选择性五羟色胺再摄取抑制剂 META分析 抑郁 焦虑
下载PDF
浙江省精神专科医院抗抑郁药临床综合评价与遴选专家共识
15
作者 《浙江省精神专科医院抗抑郁药临床综合评价与遴选专家共识》专家组 王玉文 王泽民 《中国药业》 CAS 2024年第6期1-7,共7页
目的引导和推动浙江省精神专科医院规范开展抗抑郁药的临床综合评价与遴选工作。方法浙江大学医学院附属精神卫生中心联合杭州市药事管理质量控制中心及浙江省内7家精神专科医院,广泛征求临床专家和药学专家的意见与建议,撰写了《浙江... 目的引导和推动浙江省精神专科医院规范开展抗抑郁药的临床综合评价与遴选工作。方法浙江大学医学院附属精神卫生中心联合杭州市药事管理质量控制中心及浙江省内7家精神专科医院,广泛征求临床专家和药学专家的意见与建议,撰写了《浙江省精神专科医院抗抑郁药临床综合评价与遴选专家共识》,并以13种5-羟色胺再摄取抑制剂(SSRI)和5-羟色胺去甲肾上腺素再摄取抑制剂(SNRI)为例进行试点评价。结果该共识从药学特性、安全性、有效性、经济性、创新性和其他属性6个维度对纳入的抗抑郁药进行了系统评价,并在每个维度下进行二级赋分。结论该共识的制订为抗抑郁药的快速临床综合评价与遴选提供了参考依据,同时引导和推动了相关医疗机构规范开展抗抑郁药的临床综合评价与遴选工作,以满足多元化的临床用药需求,促进临床合理用药。 展开更多
关键词 浙江省 精神专科医院 抗抑郁药 临床综合评价 药品遴选 专家共识 5-羟色胺再摄取抑制剂 5-羟色胺去甲肾上腺素再摄取抑制剂
下载PDF
5-羟色胺选择性重摄取抑制剂联合计算机化的认知训练治疗伴有认知障碍的老年抑郁症患者的研究
16
作者 朱柯蒙 汪晓 +4 位作者 周娇娇 郭城伟 马向林 任莉 张庆娥 《中国医刊》 CAS 2024年第7期746-750,共5页
目的探讨5-羟色胺选择性重摄取抑制剂(SSRI)联合计算机化的认知训练(CCT)对伴有认知障碍的老年抑郁症(LLD)患者的临床治疗效果。方法本研究为前瞻性随机对照临床研究。选取2021年5月至2022年12月于首都医科大学附属北京安定医院门诊及... 目的探讨5-羟色胺选择性重摄取抑制剂(SSRI)联合计算机化的认知训练(CCT)对伴有认知障碍的老年抑郁症(LLD)患者的临床治疗效果。方法本研究为前瞻性随机对照临床研究。选取2021年5月至2022年12月于首都医科大学附属北京安定医院门诊及住院治疗的118例伴有认知障碍的LLD患者,按照随机数表法分为干预组(57例)和对照组(61例)。干预组给予临床常规SSRI类抗抑郁药治疗联合CCT干预,对照组给予临床常规SSRI类抗抑郁药治疗联合空白对照方法,两组均治疗12周。分别在治疗前及治疗后8、12周对两组患者进行阿尔茨海默病认知评估量表(ADAS-cog)、老年抑郁量表(GDS)及日常生活能力量表(ADL)评分,以评估其认知功能、精神心理状况及社会功能。结果在治疗后8周及12周时,两组的ADAS-cog、GDS量表评分均明显低于治疗前,且干预组明显低于对照组,差异均有统计学意义(P<0.05)。治疗后8周及12周时,干预组的ADL评分明显高于治疗前,且治疗后12周干预组的ADL评分明显高于对照组,差异均有统计学意义(P<0.05),而对照组治疗前后的ADL评分比较差异无统计学意义(P>0.05)。结论SSRI类抗抑郁药联合CCT治疗能够显著改善伴有认知障碍的LLD患者的认知功能和抑郁症状,可作为该类人群的有效选择。 展开更多
关键词 老年抑郁症 认知障碍 计算机化的认知训练 5-羟色胺选择性重摄取抑制剂
下载PDF
盐酸文拉法辛缓释胶囊致低钠血症1例分析
17
作者 张弦 曲建昌 +2 位作者 赵强 徐锌 马瑞 《中国药物警戒》 2024年第7期819-821,共3页
目的探讨文拉法辛导致低钠血症的不良反应及影响因素,为临床安全用药提供参考。方法通过对1例使用盐酸文拉法辛缓释胶囊导致低钠血症病例进行分析,检索同类文献发表情况,并提出用药建议。结果患者长期使用文拉法辛治疗前庭性偏头痛5年... 目的探讨文拉法辛导致低钠血症的不良反应及影响因素,为临床安全用药提供参考。方法通过对1例使用盐酸文拉法辛缓释胶囊导致低钠血症病例进行分析,检索同类文献发表情况,并提出用药建议。结果患者长期使用文拉法辛治疗前庭性偏头痛5年后反复出现低钠血症,停用文拉法辛和对应补钠治疗后血钠逐渐恢复至正常,考虑为文拉法辛引起低钠血症。结论文拉法辛是临床上用于抑郁症治疗的主要药物之一,医生应关注文拉法辛引起低钠血症的风险,熟悉该药的适应证、禁忌证、药物相互作用和疗程,特别是高龄、女性、使用利尿剂等药物和既往有低钠血症病史的患者,用药期间定期监测电解质,从小剂量开始给药,尽早发现药品不良反应,确保患者用药安全。 展开更多
关键词 文拉法辛 选择性5-羟色胺再摄取抑制剂 抗抑郁药物 低钠血症 抗利尿激素不适当分泌综合征 药品不良反应
下载PDF
噻奈普汀与SSRI类药物比较治疗抑郁症有效性和安全性Meta分析 被引量:3
18
作者 郭静 曾粒 +3 位作者 陈建军 周林科 徐忆 谢鹏 《重庆医科大学学报》 CAS CSCD 北大核心 2014年第6期847-852,共6页
目的:评价噻奈普汀与选择性五羟色胺再摄取抑制剂(selective serotonin reuptake inhibitor,SSRI)治疗抑郁症的有效性和安全性。方法:通过检索Cochrane Library、PubMed、Web of knowledge、Embase,中国生物医学文献数据库(CBM)... 目的:评价噻奈普汀与选择性五羟色胺再摄取抑制剂(selective serotonin reuptake inhibitor,SSRI)治疗抑郁症的有效性和安全性。方法:通过检索Cochrane Library、PubMed、Web of knowledge、Embase,中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)、万方数据库(CECDB)、维普中文科技期刊全文数据库(CQVIP),筛选随机对照试验(randomized controlled trials,RCTs),并对纳入文献进行质量评价和数据提取,用Review manager 5.2软件对纳入的RCTs进行Meta分析。结果:纳入12个RCTs共2 143名患者,其中噻奈普汀治疗组1 086例,SSRI药物治疗组1 057例。Meta分析结果指出噻奈普汀治疗组患者有效率与SSRI药物治疗组有效率,无统计学差异(有效率RR=1.01,95%CI=0.95~1.07,P=0.85),且噻奈普汀治疗组恶心、呕吐、便秘、失眠与食欲减退的发生率明显低于SSRI药物治疗组(P〈0.05),而嗜睡的发生率高于SSRI药物治疗组;其余的副反应发生率比较均无统计学意义(P〉0.05)。结论:虽然噻奈普汀治疗抑郁症与SSRI药物治疗抑郁症的疗效没有统计学意义,但是其副反应明显低于SSRI类药物,故对临床用药有一定的指导意义。 展开更多
关键词 噻奈普汀 选择性五羟色胺再摄取抑制剂 抑郁症 META分析
下载PDF
脑血管病常规药物联合SSRI类抗抑郁药物治疗脑卒中后抑郁的疗效分析 被引量:7
19
作者 张丽君 黄奕平 《中西医结合心脑血管病杂志》 2020年第3期511-514,共4页
目的分析脑血管病常规药物联合5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药物治疗脑卒中后抑郁的价值。方法选取2015年3月—2017年3月我院收治的脑卒中后抑郁病人150例为研究对象,按照随机数字表法均分成对照组和研究组,各75例。对照组给予... 目的分析脑血管病常规药物联合5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药物治疗脑卒中后抑郁的价值。方法选取2015年3月—2017年3月我院收治的脑卒中后抑郁病人150例为研究对象,按照随机数字表法均分成对照组和研究组,各75例。对照组给予脑血管病常规药物治疗,研究组则给予脑血管病常规药物联合SSRI类抗抑郁药物治疗。比较两组临床疗效、汉密尔顿抑郁量表(HAMD)评分、认知功能量表(MMSE)评分、Barthel指数以及不良反应发生情况等。结果研究组治疗总有效率为88.00%,明显高于对照组的72.00%(P<0.05)。治疗后研究组与对照组HAMD评分均明显低于治疗前,且研究组明显低于对照组(P<0.05)。治疗后研究组MMSE评分、Barthel指数评分分别为(29.15±6.81)分、(86.33±11.48)分,均明显高于对照组的(24.97±6.20)分、(75.01±12.05)分,差异有统计学意义(P<0.05)。研究组恶心呕吐、头晕以及口干发生率与对照组相比差异无统计学意义(P>0.05)。结论脑血管病常规药物联合SSRI类抗抑郁药物治疗脑卒中后抑郁疗效明显,可有效促进病人神经功能与生活能力的恢复。 展开更多
关键词 脑卒中 抑郁 5-羟色胺再摄取抑制剂 汉密尔顿抑郁量表 认知功能量表
下载PDF
Possible association of the 5-HTTLPR serotonin transporter promoter gene polymorphism with premature ejaculation in a Turkish population 被引量:19
20
作者 Emin Ozbek Ali I. Tasci +5 位作者 Volkan Tugcu Yusuf O. Ilbey Abdulmuttalip Simsek Levent Ozcan Emre C. Polat Vedat Koksal 《Asian Journal of Andrology》 SCIE CAS CSCD 2009年第3期351-355,共5页
We evaluated the genotypes of the serotonin transporter gene (5-HTT) in patients with premature ejaculation (PE) to determine the role of genetic factors in the etiopathogenesis of PE and possibly to identify the ... We evaluated the genotypes of the serotonin transporter gene (5-HTT) in patients with premature ejaculation (PE) to determine the role of genetic factors in the etiopathogenesis of PE and possibly to identify the patient subgroups. A total of 70 PE patients and 70 controls were included in this study. All men were heterosexual, had no other disorders and were either married or in a stable relationship. PE was defined as ejaculation that occurred within 1 min of vaginal intromission. Genomic DNA from patients and controls was analyzed using polymerase chain reaction, and allelic variations of the promoter region of the serotonin transporter gene (5-HTTLPR) were determined. The 5-HTTLPR (serotonin transporter promoter gene) genotypes in PE patients vs. controls were distributed as follows: L/L 16% vs. 17%, L/S 30% vs. 53% and S/S 54% vs. 28%. We examined the haplotype analysis for three polymorphisms of the 5-HTTLPR gene: LL, LS and SS. The appropriateness of the allele frequencies in the 5-HTTLPR gene was analyzed by the Hardy-Weinberg equilibrium using the Z-test. The short (S) allele of the 5-HTTLPR gene was significantly more frequent in PE patients than in controls (P 〈 0.05). We suggest that the 5-HTTLPR gene plays a role in the pathophysiology of all primary PE cases. Further studies are needed to evaluate the relationship between 5-HTTLPR gene polymorphism and patient subgroup (such as primary and secondary PE) responses to selective serotonin reuptake inhibitors as well as ethnic differences. 展开更多
关键词 5-HTTLPR POLYMORPHISM premature ejaculation selective serotonin reuptake inhibitors serotonin transporter gene
下载PDF
上一页 1 2 10 下一页 到第
使用帮助 返回顶部